Dr Reddys Laboratories (RDY) Gross Margin (2009 - 2023)

Dr Reddys Laboratories (RDY) posted quarterly Gross Margin of 58.7% for Q2 2023, little changed quarter-over-quarter from 58.69% in Q1 2023.

Dr Reddys Laboratories (RDY) Gross Margin (2009 - 2023) Analysis & Trends

Dr Reddys Laboratories' Gross Margin history runs 15 years deep, the most recent figure standing at 58.7% for Q2 2023.

In Q2 2023, Gross Margin changed N/A year-over-year to 58.7%; the TTM figure through Jun 2023 stood at 59.22% (changed N/A YoY), while the FY2026 annual figure was 52.77%, down 575.0% from the prior year.
Gross Margin for Q2 2023 stood at 58.7%, roughly flat from 58.69% in the prior quarter.
The five-year high for Gross Margin was 59.22% in Q3 2022, with the low at 51.65% in Q1 2019.
The 5-year median for Gross Margin is 55.07% (2019), against an average of 55.55%.
The sharpest annual moves came in 2019 and 2020: Gross Margin tumbled 410 bps in 2019, then jumped 442 bps in 2020.
Dr Reddys Laboratories' Gross Margin stood at 54.07% in 2019, then dropped by 1 bps to 53.78% in 2020, then slipped by 1 bps to 53.41% in 2021, then grew by 7 bps to 57.24% in 2022, then increased by 3 bps to 58.7% in 2023.
Business Quant data shows RDY's Gross Margin at 58.7% in Q2 2023, 58.69% in Q1 2023, and 57.24% in Q4 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Gross Margin (Qtr)
1	Haleon	43.89 Bn	42.93 Bn	-	-
2	Teva Pharmaceutical Industries	43.01 Bn	39.35 Bn	2.15 Bn	51.98%
3	Zoetis	31.52 Bn	29.84 Bn	1.05 Bn	42.63%
4	Takeda Pharmaceutical	28.61 Bn	22.81 Bn	5.10 Bn	66.66%
5	United Therapeutics	22.17 Bn	19.51 Bn	683.80 Mn	87.30%
6	Viatris	18.73 Bn	17.85 Bn	1.46 Bn	38.77%
7	Neurocrine Biosciences	15.51 Bn	15.12 Bn	935.80 Mn	97.58%
8	Elanco Animal Health	11.75 Bn	11.22 Bn	798.00 Mn	58.33%
9	Dr Reddys Laboratories	10.12 Bn	9.96 Bn	-	-
10	Alkermes	8.12 Bn	7.46 Bn	397.90 Mn	80.22%

Download Data